The REDUCE-IT study was designed to evaluate the effectiveness of icosapent ethyl, in reducing cardiovascular risk. Specifically, it tested whether adding icosapent ethyl to statin therapy could lower the risk of major cardiovascular events—such as heart attacks, strokes, and cardiovascular death—in patients with elevated triglyceride levels despite being on statins.
The obvious question—even a fifth grader would ask—was: would it work without the statin? Why wasn’t a statin-intolerant branch included in the study? Missing this critical piece has cost people billions of dollars. If that’s not gross incompetence, I don’t know what is.
What Ralphey Says
Dont run a study well and your stock will go to hell
Market Data 
Markets 
AI
